Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

被引：24
|
作者：
Balar, Arjun Vasant
Castellano, Daniel E.
O'Donnell, Peter H.
Grivas, Petros
Vuky, Jacquiline
Powles, Thomas
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
284
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
    O'Donnell, Peter H.
    Grivas, Petros
    Balar, Arjun Vasant
    Bellmunt, Joaquim
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    De Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Lunceford, Jared K.
    Keefe, Stephen Michael
    Bajorin, Dean F.
    Castellano, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
    Grivas, Petros
    Plimack, Elizabeth R.
    Balar, Arjun, V
    Castellano, Daniel
    O'Donnell, Peter H.
    Bellmunt, Joaquim
    Powles, Thomas
    Hahn, Noah M.
    de Wit, Ronald
    Bajorin, Dean F.
    Ellison, Misoo C.
    Frenkl, Tara L.
    Godwin, James L.
    Vuky, Jacqueline
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (03): : 351 - 359
  • [3] KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)-Updated response and survival results.
    O'Donnell, Peter H.
    Balar, Arjun Vasant
    Vuky, Jacqueline
    Castellano, Daniel E.
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Grivas, Petros
    Hahn, Noah M.
    Plimack, Elizabeth R.
    Savage, Mary J.
    Fang, Xiao
    Godwin, James Luke
    Frenkl, Tara L.
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
    Grivas, P.
    Plimack, E.
    Balar, A. V.
    Castellano, D.
    O'Donnell, P. H.
    Bellmunt, J.
    Powles, T.
    Hahn, N.
    de Wit, R.
    Bajorin, D.
    Ellison, M. C.
    Frenkl, T.
    Keefe, S. M.
    Vuky, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2017, 18 (11): : 1483 - 1492
  • [6] Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
    Vuky, Jacqueline
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean
    Hahn, Noah M.
    Savage, Mary J.
    Fang, Xiao
    Godwin, James Luke
    Frenkl, Tara L.
    Moreno, Blanca Homet
    de Wit, Ronald
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (23) : 2658 - +
  • [7] First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.
    O'Donnell, Peter H.
    Balar, Arjun Vasant
    Vuky, Jacqueline
    Castellano, Daniel
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Grivas, Petros
    Hahn, Noah M.
    Plimack, Elizabeth R.
    Xu, Jin Zhi
    Godwin, James Luke
    Moreno, Blanca Homet
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
    Vuky, Jacqueline
    Balar, Arjun Vasant
    Castellano, Daniel E.
    O'Donnell, Peter H.
    Grivas, Petros
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Hahn, Noah M.
    De Wit, Ronald
    Savage, Mary
    Pang, Lei
    Frenkl, Tara L.
    Keefe, Stephen Michael
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
    Balar, A.
    Bellmunt, J.
    O'Donnell, P. H.
    Castellano, D.
    Grivas, P.
    Vuky, J.
    Powles, T.
    Plimack, E. R.
    Hahn, N. M.
    de Wit, R.
    Pang, L.
    Savage, M. J.
    Perini, R.
    Keefe, S.
    Bajorin, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab).
    Jain, Rohit K.
    Swami, Umang
    Bilen, Mehmet Asim
    Boucher, Kenneth M.
    Brown, Jacqueline T.
    Chahoud, Jad
    Gupta, Sumati
    Agarwal, Neeraj
    Sonpavde, Guru P.
    Maughan, Benjamin L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 539 - 539
12345